Government Selling Special Human Cell Line for Virus Research
Published Date: 6/25/2026
Notice
Summary
The National Cancer Institute is offering a special human T-cell line called C8166-45 for licensing. This cell line helps scientists study viruses like HTLV-1 and HIV, which can cause serious diseases. Researchers and companies can now use this tool to develop better treatments, with licensing info available starting June 2026—no patents, just pure science power ready to roll!
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
C8166-45 Available for Licensing
The National Cancer Institute is offering the human T‑cell line C8166-45 (NIH Reference Number E-272-2007) for non-exclusive licensing. The product is fully developed, listed as Research Material/Tool, and Patents: N/A; inquiries are directed to Diptadip Dattaroy, Ph.D., phone 240-276-7092 (Dated: June 23, 2026).
Tool for Gene Therapy Safety Testing
The C8166-45 cell line is highly permissive to HIV-1 infection and is characterized as suitable for replication-competent lentiviral (RCL) assays to assess safety of gene therapy products such as lentiviral vectors. NCI highlights its use for studying HTLV-1 and HIV biology and for testing RCL assay sensitivity (NIH Reference Number E-272-2007).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
2026-19303, Submission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)
The National Institutes of Health (NIH) is asking for your thoughts on how they collect info to keep research honest and fair. This affects researchers and contractors who work with NIH, aiming to make sure everything stays clear and trustworthy. You’ve got until October 22, 2026, to share your comments—no cost changes, just a check-in to keep things running smoothly!
2026-19155, Proposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)
The NIH is updating how researchers submit their Public Health Service applications and reports before awards, starting May 25, 2026. This change aims to make data management clearer and easier, affecting anyone applying for NIH funding. They want your feedback by November 17, 2026, to help improve the process without adding extra hassle or costs.
2026-19156, Proposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)
The National Institutes of Health (NIH) wants your thoughts on updating how researchers report their progress after getting awards. This affects anyone who receives NIH funding and aims to make reporting clearer and less of a hassle. Comments are due by November 17, 2026, so don’t miss your chance to weigh in!
2026-18937, Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)
The NIH is rolling out a new online form to make reporting research cheating easier and fairer. Anyone involved with NIH research can use this form to report problems like lying or copying, even anonymously. They want your feedback by November 16, 2026, to make sure the form works well without causing extra hassle.
2026-18877, Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers
The National Cancer Institute plans to give MedGene Therapeutics an exclusive license to develop and sell special engineered cell treatments for cancers caused by HPV 16 E6. This means MedGene will have the sole right to use these inventions, potentially speeding up new cancer therapies. If you want to comment or apply for a license, you must do so by September 30, 2026.
Previous / Next Documents
Previous: 2026-12842, Government Owned Inventions Available for License: Compositions and Methods for Producing Dendritic Cell-based Vaccines With Enhanced Efficacy
The National Cancer Institute has created a new way to make cancer vaccines stronger by using special omega-3 fats to boost immune cells called dendritic cells. This could help scientists and companies develop better cancer treatments that work more effectively. If you’re in biotech or medicine, now’s the time to team up or license this exciting technology and help bring improved vaccines to patients faster.
Next: 2026-12844, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings on July 17, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding which science projects get funding. Researchers applying for grants in brain injury, neurobehavior, nanotech, and heart/lung studies should note these review dates and prepare accordingly.